5AM Ventures Beats Goal for 3rd Fund

7/7/09

5AM Ventures, a life sciences-focused early stage venture capital firm, has surpassed its $150 million target for its third fund, reports PE Hub. An SEC filing that indicates 5AM, which has offices in Waltham, MA, and Menlo Park, CA, has raised $159.2 million from 34 investors. Companies in the firm’s portfolio include Pulmatrix, a Lexington, MA-based startup developing an aerosol treatment for flu other pathogens, and Cambridge, MA-based Semprus BioSciences, which is making polymers that bond to the surface of medical devices to prevent clots and infections and to promote healing.

Roxanne is an intern in Xconomy's Boston office. You can reach her at rpalmer@xconomy.com. Follow @

By posting a comment, you agree to our terms and conditions.